167 related articles for article (PubMed ID: 25373410)
1. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.
Bria E; Di Modugno F; Sperduti I; Iapicca P; Visca P; Alessandrini G; Antoniani B; Pilotto S; Ludovini V; Vannucci J; Bellezza G; Sidoni A; Tortora G; Radisky DC; Crinò L; Cognetti F; Facciolo F; Mottolese M; Milella M; Nisticò P
Oncotarget; 2014 Nov; 5(22):11054-63. PubMed ID: 25373410
[TBL] [Abstract][Full Text] [Related]
2. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
3. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
[TBL] [Abstract][Full Text] [Related]
4. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
[TBL] [Abstract][Full Text] [Related]
5. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
6. The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation.
Melchionna R; Spada S; Di Modugno F; D'Andrea D; Di Carlo A; Panetta M; Mileo AM; Sperduti I; Antoniani B; Gallo E; Lawlor RT; Piemonti L; Visca P; Milella M; Grazi GL; Facciolo F; Chen E; Scarpa A; Nisticò P
EMBO Rep; 2020 Nov; 21(11):e50078. PubMed ID: 32909687
[TBL] [Abstract][Full Text] [Related]
7. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
8. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
[TBL] [Abstract][Full Text] [Related]
9. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
[TBL] [Abstract][Full Text] [Related]
10. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer.
Yuan A; Yu CJ; Kuo SH; Chen WJ; Lin FY; Luh KT; Yang PC; Lee YC
J Clin Oncol; 2001 Jan; 19(2):432-41. PubMed ID: 11208836
[TBL] [Abstract][Full Text] [Related]
13. BARD1: an independent predictor of survival in non-small cell lung cancer.
Zhang YQ; Bianco A; Malkinson AM; Leoni VP; Frau G; De Rosa N; André PA; Versace R; Boulvain M; Laurent GJ; Atzori L; Irminger-Finger I
Int J Cancer; 2012 Jul; 131(1):83-94. PubMed ID: 21815143
[TBL] [Abstract][Full Text] [Related]
14. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Malentacchi F; Simi L; Nannelli C; Andreani M; Janni A; Pastorekova S; Orlando C
Lung Cancer; 2009 Jun; 64(3):271-6. PubMed ID: 19022520
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer.
Li W; Zheng G; Xia J; Yang G; Sun J; Wang X; Wen M; Sun Y; Zhang Z; Jin F
Cancer Sci; 2018 Apr; 109(4):1012-1023. PubMed ID: 29397041
[TBL] [Abstract][Full Text] [Related]
16. Study on molecular mechanism of MiRNA-29a in promoting proliferation and invasion of non-small-cell lung cancer by inhibiting MTSS1.
Liu M; Zeng X; Lu YX; Mo YJ; Liao TH; Gan C; Lu XQ
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5531-5538. PubMed ID: 30229825
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
18. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
19. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
